CN102198160A - Medicine composition for treating headache or insomnia as well as preparation method and purpose thereof - Google Patents
Medicine composition for treating headache or insomnia as well as preparation method and purpose thereof Download PDFInfo
- Publication number
- CN102198160A CN102198160A CN 201110128380 CN201110128380A CN102198160A CN 102198160 A CN102198160 A CN 102198160A CN 201110128380 CN201110128380 CN 201110128380 CN 201110128380 A CN201110128380 A CN 201110128380A CN 102198160 A CN102198160 A CN 102198160A
- Authority
- CN
- China
- Prior art keywords
- medicine
- buchananiae
- fructus
- latifoliae
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicine composition for treating headache or insomnia, which is prepared by raw medicine materials in following parts by weight: 84-156 parts of helicia nilagirica bedd and 350-650 parts of ligusticum wallichii. The invention also provides a preparation method and purposes of the medicine composition. The medicine composition has advantages of outstanding medicine effect and strong controllability. The medicine composition is prepared by matching helicia nilagirica bedd with the ligusticum, thereby having the function of enhancing the treating effect together and providing a new choice for clinical diagnosis.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of angioneurotic headache or insomnia, belong to drug world.
Background technology
The sedative hypnotic of clinical treatment angioneurotic headache, insomnia mainly is divided into: barbiturates, Benzodiazepines, non-Benzodiazepines, Chinese medicine etc.It is reported that medicines such as barbiturates, Benzodiazepines, non-Benzodiazepines have tangible untoward reaction mostly,, constipation, xerostomia, headache, feel sick etc. as drowsiness.Along with people to going deep into that the aspects such as untoward reaction of these sedative hypnotic are understood, the requirement of the new drug that, high selectivity efficient to seeking, side effect are little is more and more urgent.Result of study showed in recent years, many Chinese medicine ingredients have good sedative-hypnotic effect, and untoward reaction is few, has broad prospect of application, for example gastrodine is used for the treatment of diseases such as paralysis pain, neurasthenia, neuralgia clinically, have tangible maincenter calmness, anti-frightened effect, do not find obvious toxic and side effects as yet, and evident in efficacy.Therefore, develop the advantage of diseases such as treatment by Chinese herbs headache, insomnia, develop a kind of efficient, high selectivity, the little Chinese medicine of side effect meets current clinical demand very much.
Fructus Buchananiae latifoliae is the seed of the dark green Eumeces Chinensis eye of Proteaceae mountain Euphoria (Helicia) plant (Helicia nilagirica Bedd), its effective ingredient helicide (Helicid, the P-benzaladehyde-O-beta-D-allopyranose) chemical constitution is similar to Gastrodine (Gastrodin is to methylol benzene-O-β-D-pyranglucoside).Pharmacological research shows that helicide is similar to Gastrodine to central nervous system's effect, but its sedation-analgesia effect is strong than Gastrodine, and the therapeutical effect produce effects of the headache that neurosis is caused, giddy, sleep disorder is fast.Therefore, Fructus Buchananiae latifoliae has broad application prospects at the aspects such as headache, giddy and sleep disorder that the treatment neurosis causes, existing at present is the commercially available kind helicide sheet of primary raw material with the helicide, be used to alleviate headache, giddy and the sleep disorder that neurosis causes, auxiliary treatment constitutional headache.But helicide is fat-soluble poor, is difficult to see through blood brain barrier, and its bioavailability is lower, and absolute bioavailability only has about 18%, and absorbs slowly, has limited it and has applied.It is reported, round how improving its bioavailability, research worker have been launched big quantity research, the main means of having taked are two aspects such as structural modification, medicine-releasing system optimization, but these research modes nearly all are based on the developing thought of chemical medicine, and gigantic project, resource consumption is huge, does not appear in the newspapers at present and use the research that Chinese medicine research and development thinking improves its bioavailability.
The traditional Chinese medical science is very long to headache, Insomnia therapy history, and ancients treat diseases such as headache, insomnia, use Rhizoma Chuanxiong more, and the hot Wen Xiang of Rhizoma Chuanxiong scurries, go into Liver Channel, walk and do not keep the up head, middle relieving stagnation, the descending sea of blood, gas medicine in the blood can reach the top, mountain peak on the priming, so there be " control headache and must use Rhizoma Chuanxiong " to say.The bibliographical information that present no-trump Fructus Buchananiae latifoliae still and Rhizoma Chuanxiong compatibility use.
Summary of the invention
Technical scheme of the present invention has provided a kind of pharmaceutical composition for the treatment of angioneurotic headache or insomnia.Another technical scheme of the present invention has provided this preparation of drug combination method and purposes.
The invention provides a kind of pharmaceutical composition for the treatment of angioneurotic headache or insomnia, it is the medicament that is prepared from by following raw materials by weight proportions:
Fructus Buchananiae latifoliae 84-156 part, Rhizoma Chuanxiong 350-650 part.
Further preferably, it is the medicament that is prepared from by following raw materials by weight proportions:
120 parts of Fructus Buchananiae latifoliae, 500 parts of Rhizoma Chuanxiongs.
What described Rhizoma Chuanxiong adopted is Rhizoma Chuanxiong (processed with wine), and in Chinese medicine processing, medical material all will advance the process of preparing Chinese medicine and be used as medicine, " the processed with wine ascending, processed with salt is descending, vinegar system is gone into Liver Channel ", this research is treated head disease with Rhizoma Chuanxiong, therefore needs the up head of processed with wine.
Wherein, described medicament is an oral formulations.
Wherein, described oral formulations is tablet, capsule, granule, pill or oral liquid.
The present invention also provides a kind of method of pharmaceutical compositions, and it comprises the steps:
A, take by weighing materials of weight proportions: Fructus Buchananiae latifoliae 84-156 part, Rhizoma Chuanxiong 350-650 part;
B, add water or organic solvent extraction, concentrate, add acceptable accessories or complementary composition and be prepared into medicament pharmaceutically commonly used.
The present invention also provides the purposes of this pharmaceutical composition in the medicine of preparation treatment headache.Wherein, described medicine is the medicine of treatment angioneurotic headache.Described medicine is the migrainous medicine of treatment.
The present invention also provides the purposes of this pharmaceutical composition in the medicine of preparation Cure for insomnia.
Medicine of the present invention uses raw material Fructus Buchananiae latifoliae, Rhizoma Chuanxiong compatibility, has synergistic function, can be used for the treatment headache, as angioneurotic headache and migraine, and insomnia, drug effect is clear and definite, provides a kind of new selection for clinical.
Description of drawings
Fig. 1 isolated rat test for intestinal absorption experimental provision (wherein, 1, sample tap that turns up; 2, oxygen cylinder; 3, air inlet pipe; 4, escape pipe; 5, water-bath (37 ℃); 6, serosa side liquid; 7, tyrode's solution; 8, the small intestinal capsule that turns up)
The specific embodiment
The preparation of embodiment 1 medicine of the present invention
Get Fructus Buchananiae latifoliae 120g, Rhizoma Chuanxiong 500g decocts with water, and is prepared into granule.
The preparation of embodiment 2 medicines of the present invention
Get Fructus Buchananiae latifoliae medical material 120g, water boiling and extraction 2 times, each 1.5h, 8 times of amounts merge medicinal liquid, filter, and filtrate is concentrated into relative density 1-1.05 (60 ℃), adds ethanol to concentration of alcohol 75%, leaves standstill 1h, the filtering precipitation, 60 ℃ of drying under reduced pressure of filtrate are to doing, promptly.
Get Rhizoma Chuanxiong medical material 500g, adopt percolation to extract medical material solvent ratios amount: 8 times, time: 24h, number of times: 2 times, solvent: 70% ethanol, merge percolate, 60 ℃ of decompression recycling ethanols are got concentrated solution (1g raw medicinal herbs/ml), cross the D101 macroporous adsorbent resin of handling well (internal diameter 1.8cm, high 9cm, volume 23ml), flow velocity is 2BV/h, absorption 1h washes flow velocity 2BV/h earlier with 5 times of water gagings, and then, control flow velocity 2BV/h with 6 times of amounts of 30% ethanol eluting.Collect eluent, reclaim ethanol, 60 ℃ of drying under reduced pressure are to doing, promptly.
Get above-mentioned two kinds of extracts, PEG400 and propylene glycol are an amount of, after being uniformly dispersed, fill the preparation soft capsule, 35 ℃ of dryings, promptly.
Below prove beneficial effect of the present invention by pharmacodynamics test.
The test for intestinal absorption of turning up of test example 1 isolated rat
With commercially available helicide sheet, Fructus Buchananiae latifoliae extract, Fructus Buchananiae latifoliae and medicine of the present invention (Fructus Buchananiae latifoliae 120g; Rhizoma Chuanxiong 500g) is object of study, adopts the isolated rat test for intestinal absorption of turning up, investigate its absorbing state, to estimate Fructus Buchananiae latifoliae and Rhizoma Chuanxiong component compatibility (by embodiment 2 preparations) its bioavailability situation of change afterwards.
1.1 experiment material
Day island proper Tianjin high performance liquid chromatograph (LC-10ATvp infusion pump, SPD-10Avp UV-detector, CT-10ASvp column oven); High performance liquid chromatography work station (Zhejiang intelligence reaches N2000); BP211D type electronic analytical balance (buy in German Sartorius company); 79HW-1 type constant temperature blender with magnetic force (Jintan City, Jiangsu Jin Cheng state wins experimental apparatus factory); Oxygen cylinder; Effusion meter; Teat glass.
Fructus Buchananiae latifoliae (purchasing) in lotus pond medical material market, Chengdu; Helicide reference substance (lot number: 100385-200401 purchases in Nat'l Pharmaceutical ﹠ Biological Products Control Institute); Acetonitrile (chromatographically pure is bought the company in Fisher); Water (redistilled water, self-control); Micropore filter (0.45 μ m buys the company in Millipore); Other reagent is analytical pure; SD rat (♂, 180～220g).
1.2 content assaying method
1.2.1 chromatographic condition
Chromatographic column: F door Luna-C
18(4.6 * 250mm, 5 μ m); Mobile phase: acetonitrile-water-glacial acetic acid (8: 91: 1); Flow velocity: 1.0mlmin
-1Column temperature: 25 ℃; Detect wavelength: 270nm; Sample size: 10 μ l; Sensitivity: AUFS=0.01; Theoretical cam curve is calculated according to helicide should not be lower than 8000.
1.2.2 standard curve is drawn
Getting accurate compound concentration is 120.8 μ g.ml
-1Standard solution, measure with above-mentioned chromatographic condition sample introduction, (μ g) is X with sample size, peak area (mv*min) is Y, does linear regression, the results are shown in Table 1, regression equation is: Y=3 * 10
6X+15283, helicide is in 0.0031～1.2080 μ g scope internal linear relation good (r=0.9998).
Table 1. linearity and range
The test for intestinal absorption 1.3 isolated rat turns up
Before the experiment with rat overnight fasting (can freely drink water), after disconnected cervical vertebra is put to death, open the abdominal cavity along ventrimeson after, the taking-up jejunum places the tyrode's solution of ice bath, aerating oxygen, removal mesentery.After cleaning with ice-cold tyrode's solution, intestinal segment is softly overturn with little Glass rod, make intestinal mucosa towards outside, serosa side is inside, ligation intestinal anus side will be fixed in sample tap on the intestinal.Fill with blank bench teat liquid as acceptable solution from sample tap to enteral with syringe, then it is vertically put into test liquid, experimental provision is seen Fig. 1, and aerating oxygen in test tube, whole device are put into 37 ℃ of waters bath with thermostatic control and experimentized.Respectively at 10,15,30,45,60min, the 0.5ml that takes a sample in the intestinal capsule, the filtering with microporous membrane of 0.45 μ m, the filtrate ice bath is preserved, and measures according to the said method sample introduction, replenishes 37 ℃ of blank bench teat liquid of 0.5ml simultaneously in the intestinal capsule.
1.4 evaluation index
With accumulation infiltration capacity, multiple is that index is estimated the absorbing state of each medicine.
1.5 date processing
Accumulative total transit dose (Q), multiple (R) adopt following formula to calculate:
(Q: the accumulation infiltration capacity of time t; Helicide concentration in the Cn:t time reception tank; V: liquor capacity in the reception tank; Vi: sample volume; Helicide concentration in the reception tank before the Ci:t time; Q sheet: the accumulation infiltration capacity of helicide sheet; C sheet: the initial concentration of helicide sheet; R: the multiple of comparing with helicide sheet accumulation infiltration capacity)
1.6 result and analysis
By the result as can be known, the accumulation infiltration capacity of Fructus Buchananiae latifoliae is 2.25 times of helicide sheet, and the accumulation infiltration capacity of component compatibility is 6.44 times of helicide sheet, illustrates that the absorbing state of Fructus Buchananiae latifoliae extract is better than helicide, and behind the Rhizoma Chuanxiong (processed) component compatibility, its bioavailability significantly improves.
The test for intestinal absorption of turning up of table 2. isolated rat
Test example 2 medicines are to the influence of mice autonomic activities
With commercially available helicide sheet, Fructus Buchananiae latifoliae extract, Rhizoma Chuanxiong (processed) extract, Fructus Buchananiae latifoliae and medicine of the present invention (Fructus Buchananiae latifoliae 120g: Rhizoma Chuanxiong 500g) be object of study, adopt the influence of medicine to the mice autonomic activities, investigate its drug effect, with its pharmacodynamic change situation behind evaluation Fructus Buchananiae latifoliae and the Rhizoma Chuanxiong component compatibility.
2.1 experiment material
KM mice (♂, 18～22g); ZZ-6 type mice autonomic activities tester; Electronic analytical balance.
2.2 animal grouping
With picric acid animal is numbered, adopts random digit that animal is carried out the stratified random grouping.
Grouping of table 3. animal and administration
2.3 animals administer
This experimental animal feeding began the prospective adaptation environment 3 days in pharmacological evaluation animal observation ward of Chengdu University of Traditional Chinese Medicine in experiment, normally gave diet and water.And before beginning, formal experiment writes down the autonomic activities number of times of respectively organizing in the mice 5min with ZZ-6 type mice autonomic activities tester, respectively each group mice is carried out the ip administration according to " animal grouped table ", behind 6d administration 45min, write down the autonomic activities number of times of respectively organizing in the mice 5min with ZZ-6 type mice autonomic activities tester.
2.4 evaluation index
Observation index is the autonomic activities rate of change, that is:
2.5 date processing
Experimental data is represented with mean ± S.D., adopts SPSS software, statistical test one factor analysis of variance, test level α=0.05 or 0.01.
2.6 result and analysis
By the result as can be known, helicide sheet, each dosage group of Fructus Buchananiae latifoliae, each dosage group of compatibility all have remarkable inhibitory action (p＜0.05) to the mice autonomic activities; And each dosage group of Rhizoma Chuanxiong (processed) does not all have inhibitory action.Fructus Buchananiae latifoliae height, middle dosage group significantly are better than helicide sheet (p＜0.05) to mice autonomic activities inhibitory action; Compatibility height, middle dosage group significantly are better than helicide sheet (p＜0.05) to mice autonomic activities inhibitory action; Under the same dose, the compatibility group significantly is better than Fructus Buchananiae latifoliae group (p＜0.05) to mice autonomic activities inhibitory action, illustrates that the drug effect of Fructus Buchananiae latifoliae extract is better than the helicide sheet, and with the Rhizoma Chuanxiong (processed) component compatibility after, its drug effect significantly improves.
Table 4. medicine to the influence of mice autonomic activities (mean ± S.D., n=10)
Test example 3 medicines are to the influence of mouse sleep time
With commercially available helicide sheet, Fructus Buchananiae latifoliae extract (pressing the method preparation of embodiment 2), Rhizoma Chuanxiong (processed) extract, Fructus Buchananiae latifoliae and medicine of the present invention (Fructus Buchananiae latifoliae 120g: Rhizoma Chuanxiong 500g, by embodiment 2 preparations) be object of study, adopt the influence of medicine to the mice autonomic activities, investigate its drug effect, with its pharmacodynamic change situation behind evaluation Fructus Buchananiae latifoliae and the Rhizoma Chuanxiong component compatibility.
3.1 experiment material
KM mice (♂, 18～22g); Pentobarbital sodium; Electronic analytical balance.
3.2 animal grouping
With content under " test example 2 " item.
3.3 animals administer
This experimental animal feeding began the prospective adaptation environment 3 days in pharmacological evaluation animal observation ward of Chengdu University of Traditional Chinese Medicine in experiment, normally gave diet and water.Respectively each group mice is carried out the ip administration according to " animal grouped table ", (50mg/kg 0.1ml/10g), writes down each treated animal length of one's sleep in 6d administration 45min pneumoretroperitoneum injection pentobarbital sodium.
3.4 evaluation index
To be sleeping index more than the mice righting reflex loss 1min, be sleep time from righting reflex loss to recovery time.
3.5 date processing
With content under " test example 2 " item.
3.6 result and analysis
By the result as can be known, helicide sheet, each dosage group of Fructus Buchananiae latifoliae, each dosage group of compatibility all have significant prolongation effect (p＜0.05) to mouse sleep time; And all not prolongation effects of each dosage group of Rhizoma Chuanxiong (processed).Fructus Buchananiae latifoliae height, middle dosage group significantly are better than helicide sheet (p＜0.05) to mouse sleep time prolongation effect; Compatibility height, middle dosage group significantly are better than helicide sheet (p＜0.05) to mouse sleep time prolongation effect; Under the same dose, the compatibility group significantly is better than Fructus Buchananiae latifoliae group (p＜0.05) to mouse sleep time prolongation effect, illustrates that the drug effect of Fructus Buchananiae latifoliae extract is better than the helicide sheet, and with the Rhizoma Chuanxiong (processed) component compatibility after, its drug effect significantly improves.
Table 5. medicine to the influence of mouse sleep time (mean ± S.D., n=10)
To sum up, turn up test for intestinal absorption, medicine to the influence of mice autonomic activities, the medicine experiment confirms such as influence to mouse sleep time by isolated rat, according to big Rhizoma Chuanxiong side, adopt Fructus Buchananiae latifoliae and Rhizoma Chuanxiong to carry out bioavailability and the drug effect (p＜0.05) that component compatibility can significantly strengthen helicide.
Test example 4 Drug therapy nitroglycerin of the present invention cause the test of rat migraine
1 experimental technique
This experimental animal feeding began the prospective adaptation environment 3 days in pharmacological evaluation animal observation ward of Chengdu University of Traditional Chinese Medicine in experiment, normally gave diet and water.Press table 6 and prevent ig administration 3d before modeling, 4d is except that blank group subcutaneous injection equal-volume normal saline, and when daily weight subcutaneous injection Nitro-Bid 10mg/kg modeling 1 time, it is subcutaneous that subcutaneous injection is positioned right shoulder by rat for all the other each groups.After the modeling about 3min, animal occurs that ears are rubescent, forelimb is frequently scratched one's head, climb phenomenons such as cage increased frequency, dysphoria, and this phenomenon continues about 3h, occurs curling oneself up then, and movable minimizing state shows the success of migraine animal model replication.Behind the modeling 4h, 10% chloral hydrate (0.35ml/100g) ip anesthesia, take out cerebral tissue, must on the ice platform, carry out during operation, take out whole brain tissue's (rejecting cerebellum) in the 1min, with ice-cold normal saline flushing, remove bloodstain, filter paper is wiped away dried, cuts the brain stem and the hypothalamus part that contain rapheal nuclei, locus coeruleus, drop in the liquid nitrogen immediately and solidify, standby; Prepare brain tissue homogenate during mensuration, measure the content of cerebral tissue 5-hydroxy tryptamine (5-HT), calcitonin-gene-related peptide (CGRP).
Grouping of table 6. animal and dosage
2 evaluation indexes
Content with cerebral tissue 5-hydroxy tryptamine (5-HT), calcitonin-gene-related peptide (CGRP) is that index is estimated the drug effect of each medicine.
3 date processing
Adopt SPSS software, statistical test is with t check and single factor F are checked test level α=0.05 in groups.
4 interpretations of result
By 5-HT and CGRP index respectively organize data analysis as can be known, between 1. blank group and the model group significant difference (P＜0.05) is arranged, illustrate that the animal model modeling successfully.2. Fructus Buchananiae latifoliae, Fructus Buchananiae latifoliae+Rhizoma Chuanxiong all and between the model group have significant difference (P＜0.05), illustrate that Fructus Buchananiae latifoliae, Fructus Buchananiae latifoliae+Rhizoma Chuanxiong all have good therapeutical effect to the migraine due to the nitroglycerin.In addition, Fructus Buchananiae latifoliae+Rhizoma Chuanxiong effect is better than single with Fructus Buchananiae latifoliae (P＜0.05), and disclosing Rhizoma Chuanxiong can increase drug effect.
Table 7. nitroglycerin cause rat migraine animal model experiment result (mean ± S.D., n=10)
Annotate:
★: compare P＜0.05 with model
△: compare P＜0.05 with Fructus Buchananiae latifoliae
In sum, medicine of the present invention uses raw material Fructus Buchananiae latifoliae, Rhizoma Chuanxiong compatibility, has synergistic function, can be used for the treatment headache, and as angioneurotic headache and migraine, insomnia, drug effect is clear and definite, provides a kind of new selection for clinical.
The best proportioning screening test of test example 5 medicine materials of the present invention
1 experimental technique
With content under " test example 4 " item, wherein, the animal grouping is as shown in table 8 with dosage.
Grouping of table 8. animal and dosage
2 evaluation indexes
With content under " test example 4 " item.
3 date processing
With content under " test example 4 " item.
4 interpretations of result
By 5-HT and CGRP index respectively organize data analysis as can be known, between 1. blank group and the model group significant difference (P＜0.05) is arranged, illustrate that the animal model modeling successfully.2. proportioning 1,2,3 all and between the model group has significant difference (P＜0.05).3. efficacy strength, proportioning 3＞proportioning 1＞proportioning 2 discloses proportioning 3 best results.
Table 9. nitroglycerin cause rat migraine animal model experiment result (mean ± S.D., n=10)
Annotate:
★: compare P＜0.05 with model group
To sum up, medicine of the present invention uses raw material Fructus Buchananiae latifoliae, Rhizoma Chuanxiong with 120: 500 ratio compatibilities, have best potentiation.
Claims (10)
1. treat the pharmaceutical composition of having a headache or having a sleepless night for one kind, it is characterized in that: it is the medicament that is prepared from by following raw materials by weight proportions:
Fructus Buchananiae latifoliae 84-156 part, Rhizoma Chuanxiong 350-650 part.
2. pharmaceutical composition according to claim 1 is characterized in that: it is the medicament that is prepared from by following raw materials by weight proportions:
120 parts of Fructus Buchananiae latifoliae, 500 parts of Rhizoma Chuanxiongs.
3. pharmaceutical composition according to claim 1 and 2 is characterized in that: it is to be active component by active component helicide in the Fructus Buchananiae latifoliae and Rhizoma Chuanxiong volatile oil, adds the medicament that acceptable accessories or complementary composition are prepared from.
4. pharmaceutical composition according to claim 3, its feature exists: described medicament is an oral formulations.
5. pharmaceutical composition according to claim 4 is characterized in that: described oral formulations is tablet, capsule, granule, pill or oral liquid.
6. method for preparing the described pharmaceutical composition of claim 1, it comprises the steps:
A, take by weighing materials of weight proportions: Fructus Buchananiae latifoliae 84-156 part, Rhizoma Chuanxiong 350-650 part;
B, add water or organic solvent extraction, concentrate, add acceptable accessories or complementary composition and be prepared into medicament pharmaceutically commonly used.
7. any described pharmaceutical composition of claim 1-5 is preparing the purposes for the treatment of in the medicine of having a headache.
8. purposes according to claim 7 is characterized in that: described medicine is the medicine of treatment angioneurotic headache.
9. purposes according to claim 7 is characterized in that: described medicine is the migrainous medicine of treatment.
Any described pharmaceutical composition of claim 1-5 the preparation Cure for insomnia medicine in purposes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101283803A CN102198160B (en) | 2010-05-06 | 2011-05-06 | Medicine composition for treating headache or insomnia as well as preparation method and purpose thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010164428.1 | 2010-05-06 | ||
| CN201010164428 | 2010-05-06 | ||
| CN2011101283803A CN102198160B (en) | 2010-05-06 | 2011-05-06 | Medicine composition for treating headache or insomnia as well as preparation method and purpose thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102198160A true CN102198160A (en) | 2011-09-28 |
| CN102198160B CN102198160B (en) | 2012-10-03 |
Family
ID=44659316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101283803A Expired - Fee Related CN102198160B (en) | 2010-05-06 | 2011-05-06 | Medicine composition for treating headache or insomnia as well as preparation method and purpose thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102198160B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105168185A (en) * | 2015-08-03 | 2015-12-23 | 王剑峰 | External patch used for assisted treatment of sleep disorder and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1586494A (en) * | 2004-07-05 | 2005-03-02 | 北京科信必成医药科技发展有限公司 | Helicidum oral disintegation tablet and its preparing method |
| CN101254261A (en) * | 2008-03-25 | 2008-09-03 | 深圳力瑞医药科技有限公司 | Pharmaceutical combination with hypnogenesis, depression resistance and angst resistance effect and method of preparing the same |
-
2011
- 2011-05-06 CN CN2011101283803A patent/CN102198160B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1586494A (en) * | 2004-07-05 | 2005-03-02 | 北京科信必成医药科技发展有限公司 | Helicidum oral disintegation tablet and its preparing method |
| CN101254261A (en) * | 2008-03-25 | 2008-09-03 | 深圳力瑞医药科技有限公司 | Pharmaceutical combination with hypnogenesis, depression resistance and angst resistance effect and method of preparing the same |
Non-Patent Citations (2)
| Title |
|---|
| 《中国中医基础医学杂志》 20070430 张妍华等 浅谈川芎在头痛中的配伍应用 第319-320页 1-10 第13卷, 第4期 * |
| 《中国医药导刊》 20080630 刘史佳等 豆腐果苷研究进展 第911-913页 1-10 第10卷, 第6期 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105168185A (en) * | 2015-08-03 | 2015-12-23 | 王剑峰 | External patch used for assisted treatment of sleep disorder and preparation method thereof |
| CN105168185B (en) * | 2015-08-03 | 2018-06-15 | 王剑峰 | A kind of external application for sleep-disorder auxiliary treatment applies and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102198160B (en) | 2012-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101156907B (en) | A pueraria root scutellaria and coptis extract | |
| CN101637503A (en) | Total flavonoids of broussonetia papyrifera extract and preparation method and application thereof | |
| CN102657823A (en) | Traditional Chinese medicine composition with anticancer effect and preparation method and detection method thereof | |
| CN1872106A (en) | Application of wild basil circle leaves in treating disease of virulence cold | |
| CN101274025A (en) | Chinese medicinal composition with functions of reducing fever, purging the intense heat and detoxicating and preparation method thereof and quality control method | |
| CN102670720A (en) | Stephania hainanensis total alkaloid extract and preparation method thereof | |
| CN102743401A (en) | Application of panaxadiol saponins fraction in preparing medicine for preventing epilepsia | |
| CN103304518B (en) | Sesquiterpenoids and pharmaceutical composition thereof, and application of pharmaceutical composition in pharmacy | |
| CN102198160B (en) | Medicine composition for treating headache or insomnia as well as preparation method and purpose thereof | |
| CN103099862B (en) | External preparation for treating rheumatism pain disease, as well as preparation method and application thereof | |
| CN103638450B (en) | A kind of preparation method of Muxiangliqi Tablet and application | |
| CN105497713A (en) | Preparation method of inflammation diminishing and cough relieving preparation | |
| CN103908631A (en) | Traditional Chinese medicinal compound extract with anti-breast hyperplasia effect and preparation method thereof | |
| CN101396492A (en) | Quality control method for toxin ingredient, yunaconitine in Yuannan Hongyao capsule | |
| CN104888021A (en) | Vitamin C honeysuckle-phillyrin tablets | |
| CN103919885B (en) | A kind of preparation method of soft capsule for nasosinusitis and application | |
| CN103977354A (en) | Chinese medicinal extract with anti-depression effect and preparation method and application thereof | |
| CN103655841B (en) | Preparation method of Yikangbuyuan tablet and application of Yikangbuyuan tablet in medicines for inhibiting mouse lymphoid cancer cell P388D1 proliferation | |
| CN103655839B (en) | Preparation method of Yikangbuyuan tablet and application of Yikangbuyuan tablet in medicines for inhibiting mouse lung cancer cell LLC proliferation | |
| CN102614278A (en) | Changyanning preparation and method for preparing same | |
| CN104288658A (en) | Preparation method of fomes officinalis cough and asthma treating tablets and application of fomes officinalis cough and asthma treating tablets in preparation of medicine for inhibiting cell proliferation of mouse myeloma cell SP2/0 | |
| CN105663626A (en) | Rhizoma anemarrhenae effective part as well as preparation method and application thereof | |
| CN105079567A (en) | Sugar-free Sangju (mulberry leaf and chrysanthemum) cold treating granules and preparation method thereof | |
| CN103655838B (en) | Preparation method of Yikangbuyuan tablet and application of Yikangbuyuan tablet in medicines for inhibiting mouse lymphomata cell L5178Y proliferation | |
| CN101085297B (en) | Traditional Chinese medicine freeze dried injection for curing cerebral infarction and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: CHENGDU ZHONGJI MEDICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: CHENGDU KEER MEDICAL TECHNOLOGY CO., LTD. Effective date: 20141223 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 610041 CHENGDU, SICHUAN PROVINCE TO: 610000 CHENGDU, SICHUAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141223 Address after: 610000 No. 134, Xiaojiahe street, hi tech Zone, Sichuan, Chengdu Patentee after: Chengdu Zhongji Medical Technology Co Ltd Address before: 610041 No. 29 Tian Xiao street, Chengdu, Sichuan, Wuhou District Patentee before: Chengdu Keer Medical Technology Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121003 Termination date: 20170506 |